-
Integrating Stakeholder Willingness-to-Pay Using the Van Westendorp Price Sensitivity Meter Into Cost-Effectiveness Analysis: A Mixed-Methods Pricing Framework
Sep 9, 2025, 16:22 PM -
The Acceptability of Wearables in Remote Monitoring According to Health Technology Assessment HTA Bodies
Sep 9, 2025, 16:22 PM -
Navigating Implementation of the EU HTA Regulation for Medical Devices: Insights From National HTA Bodies Across Europe
Sep 9, 2025, 16:22 PM -
Healthcare Costs in People With Type 2 Diabetes Remaining on or Escalating From Basal-Supported Oral Therapy: A 5-Year German Statutory Health Insurance Claims Data Analysis
Sep 9, 2025, 16:22 PM -
Effect of Dose Interval of Oral Sulfate Solution on Bowel Preparation Quality: A Multicenter Noninferiority Randomized Controlled Trail
Sep 9, 2025, 16:22 PM -
Out of Sight, Out of Mind? A Simulation Study Assessing the Use of Quantitative Bias Analysis for Outcome Misclassification in Single-Arm Trials With External Control Comparisons
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Generalizing the Lp(a) Dosing in Secondary Prevention in a Population of French Patients With Cardiovascular Disease
Sep 9, 2025, 16:22 PM -
Quantification of Life-Cycle Value Using Early Modeling to Support RD and Strategy Decisions: A Case Study of a Polymeric Heart Valve
Sep 9, 2025, 16:22 PM -
What Does the New ILAP Refresh Mean for Pharmaceutical Development and Patient Access in the UK?
Sep 9, 2025, 16:22 PM -
Quality of Systematic Reviews With Network Meta-Analyses on JAK Inhibitors in the Treatment of Rheumatoid Arthritis: Application of the AMSTAR 2 Scale
Sep 9, 2025, 16:22 PM -
Assessing Time Tradeoff Utilities in Health States of Organic Hypogonadotropic Hypogonadism: A Pilot Study in Brazil
Sep 9, 2025, 16:22 PM -
The Effect of Drug Tracking Implementation (RSD) System on Operational Efficiency in the Saudi Healthcare Supply Chain
Sep 9, 2025, 16:22 PM -
Health-Related Quality of Life Impacts of Living With Primary Lateral Sclerosis (PLS): The Development of a Conceptual Model
Sep 9, 2025, 16:22 PM -
Real-World Evidence Study on the Resource Impact of Subcutaneous vs. Intravenous Atezolizumab in an NHS Cancer Center
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in Spain
Sep 9, 2025, 16:22 PM -
Treatments for Children With Newly Diagnosed Medulloblastoma: A Systematic Review Of Randomized Controlled Trials
Sep 9, 2025, 16:22 PM -
EUROCOVER-CLL: Reimbursement and Accessibility of New Treatments in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Final Analysis
Sep 9, 2025, 16:22 PM -
Modeling Treatment-Free Remission Outcomes for Asciminib in Newly Diagnosed Chronic Myeloid Leukemia: Assumptions, Methodology, and Projections
Sep 9, 2025, 16:22 PM -
Lessons From the NHS AI Awards: Experience of Evaluating AI Tools in Real-World Environments
Sep 9, 2025, 16:22 PM -
Insights on Progress Toward Patient-Centered HTA Through Evaluation of PRO Integration, Value Disconnects, and Policy Change in the EU5
Sep 9, 2025, 16:22 PM